Department of Cell Research and Immunology, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.
World J Gastroenterol. 2011 Dec 28;17(48):5305-9. doi: 10.3748/wjg.v17.i48.5305.
To investigate the existence and levels of sH2a, a soluble secreted form of the asialoglycoprotein receptor in human serum.
Production of recombinant sH2a and development of a monoclonal antibody and an enzyme-linked immunosorbent assay (ELISA). This assay was used to determine the presence and concentration of sH2a in human sera of individuals of both sexes and a wide range of ages.
The recombinant protein was produced successfully and a specific ELISA assay was developed. The levels of sH2a in sera from 62 healthy individuals varied minimally (147 ± 19 ng/mL). In contrast, 5 hepatitis C patients with cirrhosis showed much decreased sH2a levels (50 ± 9 ng/mL).
Constant sH2a levels suggest constitutive secretion from hepatocytes in healthy individuals. This constant level and the decrease with cirrhosis suggest a diagnostic potential.
研究人血清中作为去唾液酸糖蛋白受体可溶性分泌形式的 sH2a 是否存在及其水平。
生产重组 sH2a 并开发单克隆抗体和酶联免疫吸附测定（ELISA）。该测定法用于确定两性和广泛年龄段个体的人血清中 sH2a 的存在和浓度。
成功生产重组蛋白，并开发了一种特异性 ELISA 测定法。来自 62 名健康个体的血清中 sH2a 的水平变化很小（147 ± 19 ng/mL）。相比之下，5 名患有肝硬化的丙型肝炎患者的 sH2a 水平明显降低（50 ± 9 ng/mL）。
健康个体中 sH2a 水平的恒定表明其从肝细胞持续分泌。这种恒定水平和肝硬化时的降低表明其具有诊断潜力。
